Cytokinetics (CYTK) CEO Robert Blum is “very clear” that the company, which is on track for U.S. approval in September for aficamten to treat a serious heart condition, is not for sale, but added when speaking to STAT’s Adam Feuerstein ahead of the JPMorgan Healthcare Conference that neither he, nor the company’s board, will “ignore their fiduciary obligations to shareholders,” according to an article exclusive to STAT+ subscribers.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics provided milestones expected in 2025
- Cytokinetics announces EMA has validated MAA for aficamten
- Sanofi to acquire rights to develop, commercialize aficamten from Corxel
- Cytokinetics price target raised to $82 from $80 at RBC Capital
- Cytokinetics opens enrollment for COMET-HF Phase 3 trial